Bruker Reports Second-Quarter 2026 Results as Scientific Instruments Bookings Accelerate
Bruker (NASDAQ:BRKR) reported Q2 2026 revenue of $838.5M, up 5.2% (organic growth 2.8%). Scientific Instruments bookings rose 10% organically with a book-to-bill above 1.0x. Non-GAAP EPS increased to $0.49; GAAP results included a non-cash goodwill impairment. Bruker kept 2026 non-GAAP EPS guidance at $2.10-$2.15 and updated revenue guidance to $3.54B-$3.57B for currency and tax effects.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of Q2 bookings strength (BSI) and maintained 2026 non-GAAP EPS outlook, alongside guidance adjustments for currency and tax assumptions.
Market read
Investors get a fresh read on order momentum in Scientific Instruments and a guidance update that can drive estimate revisions and near-term sentiment.
What to watch
Organic revenue growth is modest (2.8% reported in the quarter), so traders should watch whether bookings-to-revenue conversion accelerates and whether U.S. academic research softness persists.
Background
Bruker is a scientific instruments and analytical tools company, with Scientific Instruments bookings used as a leading indicator for future revenue.
Ticker impact
Bruker reported Q2 revenue of $838.5M (+5.2% YoY) and 10% organic bookings growth in Scientific Instruments, with book-to-bill above 1.0x.
Near-term bias to the upside if investors focus on bookings strength and maintained non-GAAP EPS outlook; downside risk if organic revenue growth fails to follow through.
The article provides concrete Q2 revenue/EPS and segment bookings metrics plus an updated 2026 revenue range and maintained non-GAAP EPS outlook, which are direct inputs to valuation and forward estimates.
Market effects
Signals improving demand for scientific instruments and semiconductor metrology tools, potentially supportive for peers exposed to lab and semiconductor capex cycles.
No specific regional shock beyond commentary on U.S. academic research spending softness.
Currency and tax assumption changes in guidance highlight macro sensitivity for multinational instrument suppliers.
Counterpoint
The GAAP loss is dominated by a large non-cash goodwill impairment, so headline earnings quality may be weaker than the adjusted metrics suggest.
Key entities
- companyBruker
Reported Q2 2026 results, Scientific Instruments bookings growth, and updated 2026 guidance.
